Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.

Trial Details

NCT ID
NCT04823923
Phase
NA
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • blood sampling for ITK dosage
Locations (sample)
  • Marseille, France|43.29695,5.38107
  • Montpellier, France|43.61093,3.87635
  • Montpellier, France|43.61093,3.87635
  • Nîmes, France|43.83665,4.35788
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Patient followed for metastatic clear cell renal cell carcinoma.
  • Age ≥18 years old.
  • Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1 or 2
  • Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib for metastatic kidney cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →